January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
January 2026 in “Reactions Weekly” Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Cronfa (Swansea University)” Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.
January 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Intradermal dutasteride effectively and safely improves hair growth in early-stage androgenetic alopecia.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
January 2026 in “Dermatologic Therapy” Microneedling may improve hair loss treatments by enhancing drug delivery and hair growth.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
December 2025 in “Medicine - Programa de Formación Médica Continuada Acreditado” Recent advancements in hair loss treatments include new therapies and insights for different types of alopecia.
October 2025 in “Reactions Weekly” Finasteride and dutasteride may cause depression and suicidal thoughts.
The combination of oral minoxidil, oral dutasteride, and mesotherapy is the most effective and safe for hair growth in AGA.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
September 2025 in “JAAD reviews.” Finasteride and dutasteride can improve hair loss in women, but more research is needed.
September 2025 in “Dermatology and Therapy” The treatment improved hair growth and was well-received without side effects.
September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
July 2025 in “International Journal of Biological Macromolecules” The microneedle patch boosts hair growth by reducing DHT and oxidative stress.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “International Journal of Dermatology” Topical finasteride may be safer than oral finasteride, but more research is needed.